Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2021-06-17
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of donor natural kill cells and
to see how well they work in treating patients with acute myeloid leukemia that does not
respond to treatment (refractory) or has come back after a period of improvement (relapsed).
Giving natural killer cells after high dose chemotherapy may boost the patient's immune
system by helping it see the remaining cancer cells as not belonging in the patient's body
and causing it to destroy them (called graft-versus-tumor effect).
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Cancer Institute (NCI) The Leukemia and Lymphoma Society